



OPEN ACCESS

Original research

Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline embolization device treatment of intracranial aneurysms

Siming Gui ,¹ Xiheng Chen ,¹ Dachao Wei ,¹ Dingwei Deng,¹ Wei You ,¹ Xiangyu Meng ,¹ Jian Lv,¹ Junqiang Feng ,¹ Yudi Tang ,¹ Shu Yang,¹ Ting Chen,² Peng Liu ,³ Huijian Ge,³ Hengwei Jin,³ Xinke Liu,³ Yuhua Jiang,³ Wei Feng,⁴ Youxiang Li^{1,3}

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnis-2022-019680>).

¹Beijing Neurosurgical Institute, Capital Medical University, Beijing, China

²School of Biomedical Engineering, Capital Medical University, Beijing, China

³Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Beijing, China

⁴Department of Epidemiology and Health Statistics, Capital Medical University, Beijing, China

Correspondence to

Professor Youxiang Li, Department of Interventional Neuroradiology, Capital Medical University, Beijing 100054, China; liyoxiang@bjtth.org

SG, XC and DW contributed equally.

Received 27 September 2022
Accepted 5 January 2023
Published Online First
23 January 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

To cite: Gui S, Chen X, Wei D, et al. *J NeuroIntervent Surg* 2023;**15**:1187–1193.

ABSTRACT

Background Flow diverters have revolutionized the treatment of intracranial aneurysms. However, the delayed complications associated with flow diverter use are unknown.

Objective To evaluate the incidence, severity, clinical outcomes, risk factors, and dynamic changes associated with in-stent stenosis (ISS) after treatment with a Pipeline embolization device (PED).

Methods Patients who underwent PED treatment between 2015 and 2020 were enrolled. The angiographic, clinical, and follow-up data of 459 patients were independently reviewed by four neuroradiologists to identify ISS. Binary logistic regression was conducted to determine ISS risk factors, and an ISS–time curve was established to demonstrate dynamic changes in ISS after PED implantation.

Results Of the 459 treated patients, 69 (15.0%) developed ISS. At follow-up, nine patients (2.0%) with ISS demonstrated reversal, while 18 (3.9%) developed parental artery occlusion. A total of 380 patients (82.8%) achieved complete aneurysm occlusion (O’Kelly–Marotta grade D). Patients with posterior-circulation aneurysm (OR=2.895, 95% CI 1.732 to 4.838; P<0.001) or balloon angioplasty (OR=1.992, 95% CI 1.162 to 3.414; P=0.037) were more likely to develop ISS. Patients aged >54 years (OR=0.464, 95% CI 0.274 to 0.785; P=0.006) or with a body mass index of >28 kg/m² (OR=0.427, 95% CI 0.184 to 0.991; P=0.026) had a lower ISS risk. Intimal hyperplasia initiated by PED placement peaked within 1 year after the procedure, rarely progressed after 12 months, and tended to reverse within 24 months.

Conclusions ISS is a common, benign, and self-limiting complication of PED implantation in the Chinese population.

INTRODUCTION

Flow diverter (FD) treatment in patients with intracranial aneurysm is widely used because of its safety and high aneurysm occlusion rate.^{1–5} Although FDs have been available for over a decade, the complications associated with their implantation have not been thoroughly examined, especially in terms of long-term prognosis. Frequently studied complications after FD treatment include perioperative

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ In-stent stenosis (ISS) after Pipeline embolization device (PED) implantation is a common and self-limiting complication.
- ⇒ ISS is a long-term complication after PED implantation. However, the outcomes, dynamic changes, and risk factors for ISS remain unknown.

WHAT THIS STUDY ADDS

- ⇒ Patients with posterior-circulation aneurysm and balloon angioplasty are more likely to develop ISS. ISS reaches its peak at 6–12 months, and the progression is reversed within 24 months.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ We strongly recommend at least 2 years of postoperative angiographic follow-up to identify and evaluate ISS dynamically in patients undergoing PED placement.

ischemic and hemorrhagic events.^{6–11} However, other long-term complications after FD treatment, such as in-stent stenosis (ISS), have received less attention in terms of their clinical manifestation and pathology. Previous studies have shown that ISS is a rare complication after FD implantation.^{12–18} However, this complication is difficult to analyze statistically because of the very small number of total cases and lack of long-term dynamic follow-up data to evaluate the changes in ISS. Thus, the incidence and clinical and angiographic outcomes, the dynamic changes in ISS after Pipeline embolization device (PED) implantation, and the risk factors for ISS require further evaluation. In the present study, we evaluated the incidence, clinical consequences, risk factors, and dynamic changes in ISS based on postoperative follow-up after PED treatment.

METHODS

Study design and patients

In this study, all consecutive patients with intracranial aneurysm who underwent embolization using the PED (Covidien, Irvine, California, USA) at our

hospital were prospectively maintained in a database between September 1, 2015, and October 31, 2020. All patients provided written informed consent for the use of any identifiable patient photographs. The study protocol was reviewed and approved by the ethics committee, and the study adhered to the principles of the Declaration of Helsinki.

All patients underwent conventional catheter angiography during follow-up, and all angiographic images for ISS assessment were acquired from digital subtraction angiography data. Exclusion criteria included patients (1) who lacked follow-up imaging data or who were uncontactable during follow-up, (2) with missing data on demographics, aneurysm characteristics, antiplatelet regimen, procedure details, or neurological complications in the electronic medical record system, (3) with aneurysms related to arteriovenous malformations, or (4) who were unable to undergo antiplatelet aggregation therapy. A study flow chart of patient selection is shown in online supplemental figure 1.

Definition of stenosis rate

The stenosis rate (SR) was defined using the following equation:

$$SR = \left(1 - \frac{\text{No. } n \text{ follow-up In-stent artery Diameter (Dn)}}{\text{operation In-stent artery Diameter (D0)}}\right) \times 100\%$$

Definition of ISS

ISS was defined as a stenosis rate (SR) of $\geq 50\%$ at angiographic follow-up, irrespective of whether the SR was $< 50\%$ (recovery) at subsequent follow-up. According to the SR, the stenosis grade was classified as mild ($50\% \leq SR < 70\%$), severe ($70\% \leq SR < 99\%$), or parental artery occlusion ($SR = 100\%$).

Definition of anterior-circulation aneurysms and posterior-circulation aneurysms

The definitions of anterior-circulation aneurysms and posterior-circulation aneurysms are shown in online supplemental material.

Definition of aneurysm and parental artery morphology parameters

The morphology parameters assessed in this study were defined based on previous studies^{19 20} and are described in the online supplemental material.

Procedures

Dual antiplatelet therapy (DAPT) with aspirin (100 mg) combined with clopidogrel (75 mg) was administered at least 5 days prior to the procedure. All patients underwent platelet function testing at 1 day before PED placement. The protocol for platelet function testing is described in the online supplemental material. For non-responders, clopidogrel was switched to ticagrelor (180 mg once) before the procedure. Generation of the PED, the PED implantation procedure, and the duration and type of DAPT after the procedure are shown in the online supplemental material.

Follow-up and outcomes

Clinical follow-up was conducted at 3 months, 6 months, 1 year, 2 years, and occasionally longer after the PED implantation. All postoperative complications and medication compliance were recorded at follow-up. Aneurysm occlusion and morphology parameters were measured using digital subtraction angiography, and the occlusion grading was established based on the O'Kelly-Marotta grading scale.²¹ The first angiography follow-up was

conducted at 3–6 months after the PED implantation. The study outcomes included ISS occurrence, postprocedural ischemic or hemorrhagic events, and aneurysm occlusion. The status of the parental artery was also evaluated. Four neuroradiologists reviewed the imaging and endpoint events. In patients where the evaluation result was disputed, the team reached a unanimous decision after a discussion. The person in charge of the review committee supervised the reading procedures and was responsible for the accuracy and validity of the conclusions.

Statistical analysis

Continuous variables, such as demographic data, clinical records, aneurysm characteristics, and follow-up imaging results, are described as mean \pm SD or median (IQR), as appropriate, according to the data distribution (normality was proved using histograms and Q–Q plots). Categorical variables are expressed as frequency (percentage). Comparative analyses between the ISS and non-ISS groups were performed using the t-test and the non-parametric Mann–Whitney U test for continuous variables, the non-parametric Mann–Whitney U test for ordinal variables, and the χ^2 test or Fisher's exact test for categorical variables. The univariate logistic regression analysis was conducted to test the relationship between ISS and the variables mentioned above. Covariates with P values of < 0.1 in the univariate analysis were entered into the multivariate analysis using the backward stepwise selection method. All statistical analyses, including analyses to obtain crude and adjusted ORs and 95% confidence intervals, were performed using R (v4.1.1 and above; R Foundation for Statistical Computing, Vienna, Austria). All P values were based on two-tailed statistical tests, and P values < 0.05 were considered statistically significant.

RESULTS

Patient and follow-up characteristics

Between September 2015 and December 2020, a total of 459 consecutive patients (median age, 54 years (IQR 47–61 years); men, 151 (32.9%)) treated with the PED were included in this study (table 1). Sixty-nine patients (15.0%) developed ISS in the follow-up period. The median follow-up period was 9 months (IQR 6–16 months) (table 2). ISS spontaneously recovered in nine patients on final angiographic follow-up. The other 60 patients experienced ISS, 32 (53.3%) of whom developed mild ISS, 10 (16.7%) of whom developed severe ISS, and 18 (30%) of whom developed parental artery occlusion. All cases of complete parental artery occlusion were detected during the follow-up period. Subgroup analysis (online supplemental material) revealed a significant difference between the ISS resolution group and the ISS non-resolution group (25 (14–36) months vs 14 (9–20) months, respectively; $P = 0.005$) in the mean follow-up duration of patients with ISS. Of the 69 patients with ISS, four (5.8%) experienced hemiplegia, one (1.4%) experienced hemianopia, and two (2.9%) died from brainstem infarction because ISS developed into basilar artery occlusion. The number of patients with a body mass index (BMI) of $\geq 28 \text{ kg/m}^2$ in the non-ISS group ($n = 64$ (16.4%)) was significantly higher than that in the ISS group ($n = 4$ (5.8%)) ($P = 0.022$).

There was no difference in the rate of postoperative complications (ischemic or hemorrhagic) between the non-ISS and ISS groups (1.3% vs 4.3%, respectively; $P = 0.195$). A total of 380 patients (82.8%) achieved complete occlusion after stent implantation. There were no differences in the proportion of patients attaining a favorable outcome between the non-ISS group (82.1%) and the ISS group (87%) ($P = 0.32$). There were

Table 1 Baseline characteristics of patients after Pipeline embolization device (PED) treatment

Characteristics	Non-ISS (n=390)	ISS (n=69)	Total (n=459)	P value
Stenosis grade (last follow-up) (non-ISS=390, ISS=60)				—
No stenosis (SR<50%)	399 (100%)	0 (0%)	399 (86.9%)	
Mild stenosis (50%≤SR<70%)	0 (0%)	32 (53.3%)	32 (7.0%)	
Severe stenosis (70%≤SR<99%)	0 (0%)	10 (16.7%)	10 (2.2%)	
Occlusion (SR=100%)	0 (0%)	18 (30%)	18 (3.9%)	
Age	54 (48–61)	52 (46–52)	54 (47–61)	0.117
Male	122 (31.3%)	29 (42.0%)	151 (32.9%)	0.080
Height (cm)	164 (160–170)	165 (160–170)	164 (160–170)	0.443
Weight (kg)	65 (59–75)	68 (60–75)	65 (59–75)	0.764
BMI	24.61 (22.53–26.95)	24.46 (23.14–26.42)	24.56 (22.67–26.73)	0.935
Fat (BMI≥28 kg/m ²)	64 (16.4%)	4 (5.8%)	68 (14.8%)	0.022
Diabetes mellitus	35 (9.0%)	6 (8.7%)	41 (8.9%)	0.940
Dyslipidemia	163 (41.8%)	25 (36.2%)	188 (41.0%)	0.386
Hypertension	165 (42.3%)	29 (42.0%)	194 (42.3%)	0.577
Pre-SAH	20 (5.1%)	3 (4.3%)	23 (5.0%)	1.000
Pre-ischemic stroke	28 (7.2%)	4 (5.8%)	32 (7.0%)	0.874
Coronary heart disease	28 (7.2%)	6 (8.7%)	34 (7.4%)	0.658
Current smoking	61 (15.6%)	13 (18.8%)	74 (16.1%)	0.505
Regular alcohol drinkers	55 (14.1%)	11 (15.9%)	66 (14.4%)	0.161
Allergic history	52 (13.3%)	6 (8.7%)	58 (12.6%)	0.285
Preinterventional operation	25 (6.4%)	3 (4.3%)	28 (6.1%)	0.699

BMI, body mass index; ISS, in-stent stenosis; SAH, subarachnoid hemorrhage; SR, stenosis rate.

no differences in the rate of antiplatelet drug withdrawal (21.0% vs 30.4%, respectively; $P=0.116$) or the change in antiplatelet therapy (1.8% vs 2.9%, respectively; $P=0.630$) between the non-ISS and the ISS groups.

Aneurysm characteristics

We included the aneurysm characteristics of 459 patients in our statistical analysis (online supplemental table 1). Aneurysms in the non-ISS group were more frequently located in the anterior circulation, while the proportion of aneurysms in the anterior circulation was lower in the ISS group (81.9% vs 63.8%, respectively; $P=0.008$). The proportion of patients who underwent

balloon angioplasty was significantly different between the non-ISS and the ISS groups (17.4% vs 30.4%, respectively; $P=0.012$). The proportion of patients treated with the PED with coiling was similar between the non-ISS and ISS groups (37.4% vs 42%, respectively; $P=0.469$). Certain angiographic parameters, including aneurysm neck (6.69 mm (IQR 4.45–11.10) vs 10.10 mm (IQR 6.52–15.75), respectively; $P<0.001$), aneurysm maximum diameter (10.40 mm (IQR 6.29–16.70) vs 13.3 mm (IQR 9.07–22.20), respectively; $P=0.003$), aneurysm height (7.37 mm (IQR 4.76–11.80) vs 7.87 mm (IQR 6.57–14.45), respectively; $P=0.025$), aneurysm width (8.48 mm (IQR 4.81–14.63) vs 12.90 mm (IQR 6.80–20.95), respectively; $P<0.001$),

Table 2 Follow-up characteristics of patients after Pipeline embolization device (PED) treatment

Characteristics	Non-ISS (n=390)	ISS (n=69)	Total (n=459)	P value
Postoperative complications	5 (1.3%)	3 (4.3%)	8 (1.7%)	0.195
First follow-up time	7 (5–9)	6 (5–7)	6 (5–8)	0.026
First follow-up parental artery diameter	3.12 (2.60–3.66)	1.65 (0.50–2.32)	2.95 (2.32–3.53)	<0.001
First follow-up aneurysm complete occlusion	306 (78.5%)	53 (76.8%)	359 (78.2%)	0.760
Last follow-up time	9 (6–16)	12 (6–19)	9 (6–16)	0.116
Last follow-up parental artery diameter	3.12 (2.55–3.66)	1.16 (0–1.80)	2.90 (2.26–3.56)	<0.001
Last follow-up aneurysm complete occlusion	320 (82.1%)	60 (87.0%)	380 (82.8%)	0.320
Severe postoperative symptoms* related to ISS	0 (0%)	5 (7.2%)	5 (1.1%)	—
Mortality related to ISS (basilar artery occlusion)	0 (0%)	2 (2.9%)	2 (0.4%)	—
Drug withdrawal	82 (21.0%)	21 (30.4%)	103 (22.4%)	0.116
Clopidogrel switched to ticagrelor	58 (14.9%)	14 (20.3%)	72 (15.7%)	0.254

*Severe postoperative symptoms included hemidysesthesia, hemiplegia, and hemianopia. ISS, in-stent stenosis.

aneurysm perpendicular height (6.96 mm (IQR 4.50–11.23) vs 7.87 mm (IQR 5.83–14.25), respectively; $P=0.017$), height/width ratio (0.89 (IQR 0.74–1.02) vs 0.81 (IQR 0.64–0.95), respectively; $P=0.012$), size ratio (2.87 (IQR 1.64–4.73) vs 3.56 (IQR 2.18–6.32), respectively; $P=0.007$), and neck ratio (1.91 (IQR 1.15–3.02) vs 2.93 (IQR 1.56–4.40), respectively; $P<0.001$), were significantly different between the two groups.

Logistic regression analysis

The variance inflation factors of the size ratio, neck ratio, and height/width ratio were >10 in the collinearity test. Thus, we excluded these variables from the multivariate logistic regression analysis. Univariate analysis showed that the crude ORs in the ISS group with the covariates of age >54 years, BMI >28 kg/m², posterior-circulation aneurysm, and balloon angioplasty were 0.559 (95% CI 0.338 to 0.924; $P=0.023$), 0.399 (95% CI 0.161 to 0.994; $P=0.048$), 2.175 (95% CI 1.335 to 3.543; $P=0.002$), and 1.771 (95% CI 1.056 to 2.968; $P=0.03$), respectively, in comparison with the non-ISS group. After all covariates with P values <0.1 were entered into the multivariate analysis using the backward stepwise selection method, the adjusted ORs in the ISS group with covariates of age >54 years, BMI >28 kg/m², posterior-circulation aneurysm, and balloon angioplasty were 0.464 (95% CI 0.274 to 0.785; $P=0.006$), 0.427 (95% CI 0.184 to 0.991; $P=0.026$), 2.895 (95% CI 1.732 to 4.838; $P<0.001$), and 1.992 (95% CI 1.162 to 3.414; $P=0.037$), respectively, in comparison with the non-ISS group (table 3).

Dynamic changes in ISS

We constructed the subgroup ST-T curve (ISS group ($n=69$) versus non-ISS group ($n=390$); figure 1) to demonstrate the dynamic changes in parental artery diameter after PED implantation. We used the diameter changing rate (calculated as $1 - \text{SR}$) for comparison of the original diameter (measured immediately after the procedure) of the parental artery and the follow-up diameter of the parental artery to standardize the variation in vessel diameter of each patient. The diameter changing rate calculated immediately after the procedure was 1 in both the ISS and non-ISS groups. The ST-T curve showed that simultaneous and progressive endothelialization initiated by PED implantation reached its peak at 6–12 months and rarely progressed after 12 months, while intimal hyperplasia progression of ISS was reversed within 24 months.

Subgroup analysis

We conducted a subgroup analysis to compare the mean duration of follow-up between the resolution group and the non-resolution group. We conducted another subgroup analysis to identify differences in the resolution and progression to artery occlusion between patients with ISS who were receiving DAPT and those who were not, as well as a subgroup analysis to identify differences between responders and non-responders (according to the platelet function test) with respect to ISS. Finally, we evaluated the patients with ISS for evidence of proximal or distal ‘fish-mouthing’ and late distortion of the actual PED at follow-up angiography. The results of the subgroup analyses are presented in the online supplemental material.

DISCUSSION

In the present study, the incidence of ISS was approximately 15% after PED implantation for intracranial aneurysm. In the majority of patients in the ISS group, ISS developed into mild stenosis (53.2%), while ISS developed into parental artery

occlusion in approximately 30% of patients. Previous studies have shown different incidence rates (1.1%–29.3%) of ISS after PED implantation.^{12 14 16 22} However, because of the very small number of total cases and lack of long-term dynamic follow-up data for ISS findings in those studies, it is difficult to conduct further analyses on factors affecting ISS. From our large sample of patients who underwent PED implantation and who had ISS, we found that age >54 years and a BMI >28 kg/m² were protective factors for ISS, while balloon angioplasty and posterior-circulation aneurysm were risk factors for ISS.

There are marked differences in the current diagnostic criteria for ISS. ISS is commonly classified as mild (SR: 0–25%), moderate (SR: 25–50%), or severe (SR $>50\%$). Some studies have defined ISS as a reduction in blood vessel diameter of $\geq 25\%$. In the present study, we defined the occurrence of ISS as an SR of $\geq 50\%$. This definition of ISS may be too conservative and potentially created a bias in favor of PED. However, we chose this definition because mild intimal hyperplasia after stenting is expected, desirable, and required to achieve aneurysm occlusion.¹⁴ Therefore, only more robust reactive stenosis, which is probably detrimental because of hemodynamically significant flow limitations, was graded as ISS.

Our finding that ISS was less common in older people is similar to previous studies. Sweid *et al*²³ reported that advanced age was associated with a decreased capacity for endothelial regeneration, which explains the lower ISS rate. Specifically, lack of endothelialization was found in the aging brain, which reduced the potential for neural stem cell proliferation and differentiation. However, aging is a double-edged sword for patients who undergo PED implantation because a lack of endothelialization is responsible for failed aneurysm occlusion, necessitating an extended follow-up time and aneurysm re-treatment.²⁴

Patients who undergo balloon angioplasty are more likely to develop ISS after surgery. This may occur for two reasons. First, the basic cerebrovascular condition of these patients is poor, and local stenosis or atherosclerosis may be present. Moreover, blood vessels in the lesion area are relatively tortuous. Thus, the micro-catheter cannot reach the finest landing area during surgery. In this situation, if balloon angioplasty is not used, it will be difficult to ensure that the stent adheres to the vessel wall to treat the aneurysm. Second, balloon angioplasty can cause mechanical damage to the blood vessel wall, leading to intensified local inflammation and subsequent excessive intimal hyperplasia.²³ On the basis of our findings, we recommend using the PED to treat intracranial aneurysms. Nevertheless, neuroradiologists should evaluate the benefits and risks based on the condition of patients who have undergone balloon angioplasty. If balloon angioplasty is inevitable, long-term follow-up is necessary, and the antiplatelet drug treatment plan needs to be dynamically adjusted according to the results of angiographic follow-up.

In contrast to our findings, Chalouhi *et al* reported that anterior-circulation aneurysms, especially internal carotid artery aneurysms, were a risk factor for ISS after PED implantation (OR=3.1; $P=0.03$).¹³ In that study, the number of patients with posterior-circulation aneurysms was small. This might be because neuroradiologists were cautious about applying the PED to posterior-circulation aneurysms at that time, as the treatment of these aneurysms was not an original indication for PED implantation. However, indications for use of the PED have expanded with increasing data on its efficacy and safety. More recently, many studies have reported the feasibility of the PED for posterior-circulation aneurysm treatment.^{25 26} Although the proportion of aneurysms in the anterior circulation exceeded 80% in our study, considering that neuroradiologists

Table 3 Logistic regression analysis

Characteristics	Univariate analysis			Multivariate analysis		
	P value	Crude HR	95% CI	P value	Adjusted HR	95% CI
Male	0.128	1.456	0.897 to 2.363	–	–	–
Age >54 years	0.023	0.559	0.338 to 0.924	0.006	0.464	0.274 to 0.785
BMI ≥ 28 kg/m ²	0.048	0.399	0.161 to 0.994	0.026	0.427	0.184 to 0.991
Diabetes mellitus	0.721	1.165	0.504 to 2.697	–	–	–
Dyslipidemia	0.408	0.812	0.495 to 1.331	–	–	–
Hypertension	0.728	1.089	0.673 to 1.762	–	–	–
Pre-SAH	0.886	0.919	0.288 to 2.929	–	–	–
Pre-stroke	0.786	1.152	0.416 to 3.189	–	–	–
Coronary artery disease	0.677	1.195	0.517 to 2.765	–	–	–
Current smoking	0.225	1.456	0.794 to 2.671	–	–	–
Regular alcohol drinkers	0.777	1.098	0.575 to 2.096	–	–	–
Allergy	0.131	0.523	0.226 to 1.212	–	–	–
Number of PEDs used	0.864	0.937	0.446 to 1.969	–	–	–
PED associated with coils	0.813	1.060	0.653 to 1.721	–	–	–
Aneurysm location in posterior circulation	0.002	2.175	1.335 to 3.543	P<0.001	2.895	1.732 to 4.838
Aneurysm with lobulation	0.590	1.225	0.585 to 2.564	–	–	–
Aneurysm with daughter sac	0.943	0.967	0.389 to 2.408	–	–	–
Aneurysm in bifurcation	0.157	1.933	0.776 to 4.816	–	–	–
Aneurysm neck	0.109	1.020	0.995 to 1.046	–	–	–
Maximum diameter	0.124	1.018	0.995 to 1.042	–	–	–
Aneurysm height	0.164	1.023	0.991 to 1.057	–	–	–
Aneurysm width	0.058	1.022	0.999 to 1.046	–	–	–
Aneurysm perpendicular height	0.106	1.028	0.994 to 1.063	–	–	–
Aspect ratio	0.219	0.800	0.561 to 1.142	–	–	–
Height/width ratio	0.040	0.387	0.157 to 0.956	–	–	–
Bottle neck factor	0.578	0.810	0.385 to 1.702	–	–	–
Size ratio	0.030	1.081	1.008 to 1.160	–	–	–
Neck ratio	0.006	1.130	1.035 to 1.235	–	–	–
Parental artery diameter	0.557	1.089	0.819 to 1.447	–	–	–
Proximal artery diameter	0.485	1.099	0.843 to 1.434	–	–	–
Distal artery diameter	0.395	1.132	0.851 to 1.505	–	–	–
Difference between proximal and distal artery	0.929	0.986	0.732 to 1.330	–	–	–
Proximal/distal ratio	0.958	0.977	0.407 to 2.343	–	–	–
Mean artery diameter	0.382	1.147	0.843 to 1.561	–	–	–
Recurrent aneurysm	0.713	1.303	0.319 to 5.331	–	–	–
Symptomatic aneurysm	0.736	1.086	0.672 to 1.756	–	–	–
Multiple aneurysm	0.327	0.760	0.439 to 1.316	–	–	–
Unsatisfactory device deployment	0.160	1.923	0.772 to 4.79	–	–	–
Balloon angioplasty	0.030	1.771	1.056 to 2.968	0.037	1.992	1.162 to 3.414
Preinterventional operation	0.370	0.588	0.185 to 1.874	–	–	–
Last follow-up complete occlusion	0.494	0.782	0.386 to 1.584	–	–	–
Fusiform aneurysm	0.004	2.062	1.258 to 3.380	–	–	–
Drug withdrawal	0.116	1.641	0.932 to 2.903	–	–	–
Clopidogrel switched to ticagrelor	0.256	1.457	0.762 to 2.789	–	–	–

BMI, body mass index; ISS, in-stent stenosis; PED, Pipeline embolization device; SAH, subarachnoid hemorrhage.

remain cautious when deciding whether to use the PED to treat posterior-circulation aneurysms, we consider that this ratio was acceptable.

In the present study, the incidence of ISS after PED treatment for posterior-circulation aneurysms was higher than that for anterior-circulation aneurysms, and two patients died from

complications caused by basilar artery infarction due to basilar artery occlusion after ISS. Additionally, posterior-circulation aneurysms are mostly dissecting aneurysms, and typically, dissecting aneurysms are often associated with a higher rate of parent artery stenosis.²⁷ Moreover, some of the posterior-circulation aneurysms treated with the PED in the present study

ISS - Time Curves




Figure 1 In-stent stenosis (ISS)–time curves in the ISS (n=69) and non-ISS (n=390) groups. The diameter changing rate was defined as 1 – stenosis rate. Both the ISS and non-ISS groups showed a trend towards a peak in endothelialization initiated by implantation of the Pipeline embolization device at 6–12 months, which rarely progressed after 12 months. ISS was reversed within 24 months after device implantation.

were large or giant vertebrobasilar fusiform aneurysms. These aneurysms often involve a long section of the parent artery, and there is often partial thrombosis in the aneurysm sac. To adequately cover the aneurysm, treatment requires the use of multiple PEDs with overlapping placement, as well as placement across vessels of different diameters.²⁸ These factors all increase the risk of long-term postoperative ISS.

Interestingly, we found that a higher BMI was associated with decreased occurrence of ISS. To our knowledge, BMI has not been previously reported to affect ISS. Notably, West *et al*²⁹ found that restenosis after intracoronary stent placement was associated with reduced BMI, and the authors suggested that patients with a lower BMI have smaller coronary arteries than obese patients. Thus, we speculate that ISS after PED implantation may follow a similar course. Nevertheless, it remains unclear whether the higher BMI in the ISS group reflected a larger cerebral vessel diameter. Further studies are required to elucidate the reason for this finding and to explore the relationship between BMI, vessel diameter, and ISS risk.

For patients with ISS without symptoms, we prescribed atorvastatin (20 mg/day) if they had not completed 6 months of standard DAPT (aspirin combined with clopidogrel or ticagrelor). If they had completed 6 months of DAPT, we prescribed aspirin combined with atorvastatin until the next follow-up. For patients with ISS with symptoms, we prescribed atorvastatin (20 mg/day) and extended the duration of DAPT if they had not completed 6 months of DAPT. We also recommended that the patients resumed DAPT and added atorvastatin until the next follow-up if they had completed 6 months of DAPT. According to our subgroup analysis, patients with ISS had a higher resolution rate if they extended their dose or resumed DAPT (n=4 (7.8%) vs n=5 (27.8%), respectively; $P=0.045$). These data suggest that restoration or prolongation of DAPT contributes to ISS resolution, although the exact mechanism remains unclear. For patients with ISS who developed parental artery occlusion,

there was no difference between the aspirin group and the DAPT group (n=12 (22.6%) vs n=6 (26.1%), respectively; $P=0.240$).

Our results show that tissue growth in normal appearing PED occurs in the majority of patients with ISS. However, further analysis revealed that all patients who developed parental artery occlusion had late distortion of the PED. Furthermore, in two patients who died, the type of ISS involved distal distortion of the PED, suggesting that ISS caused by late flow diverter distortion is more likely to have catastrophic consequences and requires particular attention from clinicians, which is consistent with previous studies.^{12 14}

Our study demonstrated that ISS is usually asymptomatic, with only a small number of patients (7/69 (10.1%)) experiencing symptoms (eg, dizziness, hemianopsia, hemidysesthesia, and hemiplegia). ISS was reversible in most patients (51/69 (73.9%)) and sometimes improved or completely recovered without retreatment (9/69 (13.0%)), while only a small number of patients worsened (7/69 (10.1%)). Only one patient (1/69 (1.4%)), who was originally diagnosed with asymptomatic ISS, developed symptoms. This patient stopped using antiplatelet drugs without authorization because of a femur fracture 10 months after PED treatment for basilar aneurysm, and had a brainstem infarction during the 12-month follow-up. Other patients with asymptomatic in-stent stenosis (ISS) who took their prescribed medication did not develop new symptoms during follow-up. Thus, we suggest that patients with asymptomatic ISR identified during follow-up have a low risk of progression to symptomatic ISR when treated with appropriate antiplatelet drugs and statins.

Because of the relatively slow progress of ISS, not all cases were detected during the first angiographic follow-up, suggesting that ISS does not necessarily occur within 3–6 months after PED implantation. On the basis of our ST-T curve, the intimal hyperplasia initiated by PED implantation peaked and developed aggressively at 6–12 months after

implantation. Subgroup analysis showed a significant difference in average follow-up duration between the resolution group and the non-resolution group. According to the ST-T curve, patients who developed ISS showed a clear trend towards resolution at 24 months after PED implantation, which fits with our statistical analyses. For these reasons, we strongly recommend at least 2 years of postoperative angiographic follow-up to identify ISS and to dynamically evaluate the degree of intimal hyperplasia in patients undergoing PED placement. Even if ISS leads to complete blood vessel occlusion, the cerebral circulation can have abundant collateral circulation, and ISS will not cause serious symptoms as it occurs very slowly. Note that current treatment for ISS remains empirical.³⁰ For patients with ISS, close follow-up and long-term antiplatelet therapy are recommended. If the blood vessel is nearly completely occluded and causes symptoms, angioplasty, stent reimplantation, or even bypass surgery can be used to relieve blood vessel narrowing.

Limitations

Our study has several limitations. First, this was a single-center study, and the results cannot be generalized to other patient groups. However, a single-center design was chosen because we needed to control the main confounding factors. Second, all of the angiographic parameters were obtained by manual measurement. Thus, measurement errors might have biased the final results. Third, we used self-reported data to assess medication compliance during follow-up, which might have caused bias. Finally, there may be unknown confounding factors that we did not consider in our analysis that could have influenced our results.

CONCLUSION

We found that ISS after PED implantation is a common and self-limiting complication. Patients with posterior-circulation aneurysms and balloon angioplasty were more likely to develop ISS. Patients aged >54 years or with a BMI >28 kg/m² had a lower risk of ISS occurrence and progression. Intimal hyperplasia initiated by PED implantation reached its peak at 6–12 months, and ISS progression was reversed within 24 months.

Acknowledgements The authors acknowledge Dr. Ming Lv for editorial assistance. We also thank Emily Woodhouse, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing the English text of a draft of this manuscript.

Contributors All authors were involved in, and made substantial contributions to, the conception or design of the work, or the acquisition, analysis, or interpretation of the data; drafting the work or revising it critically for important intellectual content; final approval of the version published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. YL is the guarantor for this article and accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding This study was supported by the National Key Research and Development Program of China (grant No. 2017YFB1304400).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants but the data used in this study are all from a prospective database funded by the National Key Research and Development Program of China, so the ethics committee of Beijing Tiantan Hospital exempted this study. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement Data are available upon reasonable request. The authors agree to share data upon reasonable request. Any data from this study are available by contacting the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Siming Gui <http://orcid.org/0000-0002-7024-7258>
Xiheng Chen <http://orcid.org/0000-0001-9837-4710>
Dachao Wei <http://orcid.org/0000-0003-3389-8112>
Wei You <http://orcid.org/0000-0003-0466-6486>
Xiangyu Meng <http://orcid.org/0000-0002-7703-1177>
Junqiang Feng <http://orcid.org/0000-0003-0731-6510>
Yudi Tang <http://orcid.org/0000-0002-3436-7711>
Peng Liu <http://orcid.org/0000-0002-1849-9634>

REFERENCES

- Lin N, Brouillard AM, Keigher KM, *et al.* Utilization of pipeline embolization device for treatment of ruptured intracranial aneurysms: US multicenter experience. *J Neurointerv Surg* 2015;7:808–15.
- Walcott BP, Stapleton CJ, Choudhri O, *et al.* Flow diversion for the treatment of intracranial aneurysms. *JAMA Neurol* 2016;73:1002–8.
- Hanel RA, Kallmes DF, Lopes DK, *et al.* Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results. *J Neurointerv Surg* 2020;12:62–6.
- Luo B, Kang H, Zhang H, *et al.* Pipeline embolization device for intracranial aneurysms in a large chinese cohort: factors related to aneurysm occlusion. *Ther Adv Neurol Disord* 2020;13:1756286420967828.
- Lylyk I, Scrivero E, Lundquist J, *et al.* Pipeline embolization devices for the treatment of intracranial aneurysms, single-center registry: long-term angiographic and clinical outcomes from 1000 aneurysms. *Neurosurgery* 2021;89:443–9.
- Kulcsár Z, Houdart E, Bonafé A, *et al.* Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. *AJNR Am J Neuroradiol* 2011;32:20–5.
- Turowski B, Macht S, Kulcsár Z, *et al.* Early fatal hemorrhage after endovascular cerebral aneurysm treatment with a flow diverter (SILK-Stent): do we need to rethink our concepts? *Neuroradiology* 2011;53:37–41.
- Cebal JR, Mut F, Raschi M, *et al.* Aneurysm rupture following treatment with flow-diverting stents: computational hemodynamics analysis of treatment. *AJNR Am J Neuroradiol* 2011;32:27–33.
- Berge J, Tourdias T, Moreau J-F, *et al.* Perianeurysmal brain inflammation after flow-diversion treatment. *AJNR Am J Neuroradiol* 2011;32:1930–4.
- Brinjikji W, Murad MH, Lanzino G, *et al.* Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. *Stroke* 2013;44:442–7.
- Rouchaud A, Brinjikji W, Lanzino G, *et al.* Delayed hemorrhagic complications after flow diversion for intracranial aneurysms: a literature overview. *Neuroradiology* 2016;58:171–7.
- Cohen JE, Gomori JM, Moscovici S, *et al.* Delayed complications after flow-diverter stenting: reactive in-stent stenosis and creeping stents. *J Clin Neurosci* 2014;21:S0967-5868(13)00644-9:1116–22.
- Chalouhi N, Polifka A, Daou B, *et al.* In-pipeline stenosis: incidence, predictors, and clinical outcomes. *Neurosurgery* 2015;77:875–9; discussion 879.
- John S, Bain MD, Hui FK, *et al.* Long-term follow-up of in-stent stenosis after pipeline flow diversion treatment of intracranial aneurysms. *Neurosurgery* 2016;78:862–7.
- Aguilar Pérez M, Bhogal P, Henkes E, *et al.* In-stent stenosis after p64 flow diverter treatment. *Clin Neuroradiol* 2018;28:563–8.
- Ravindran K, Salem MM, Enriquez-Marulanda A, *et al.* Quantitative assessment of in-stent stenosis after pipeline embolization device treatment of intracranial aneurysms: a single-institution series and systematic review. *World Neurosurg* 2018;120:e1031–40.
- Essbahiheh F, Alqahtani H, Almansoori TM, *et al.* Transient in-stent stenosis at mid-term angiographic follow-up in patients treated with SILK flow diverter stents: incidence, clinical significance and long-term follow-up. *J Neurointerv Surg* 2019;11:166–70.
- Flores-Milan G, Pressman E, Peto I, *et al.* Factors associated with in-stent stenosis after cerebral aneurysm embolization using a pipeline embolization device. *Interv Neuroradiol* 2022;28:731–736.

- 19 Juvela S, Korja M. Intracranial aneurysm parameters for predicting a future subarachnoid hemorrhage: a long-term follow-up study. *Neurosurgery* 2017;81:432–40.
- 20 Mocco J, Brown RD, Torner JC, *et al.* Aneurysm morphology and prediction of rupture: an international study of unruptured intracranial aneurysms analysis. *Neurosurgery* 2018;82:491–6.
- 21 O'Kelly CJ, Krings T, Fiorella D, *et al.* A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. *Interv Neuroradiol* 2010;16:133–7.
- 22 Wang T, Richard SA, Jiao H, *et al.* Institutional experience of in-stent stenosis after pipeline flow diverter implantation: a retrospective analysis of 6 isolated cases out of 118 patients. *Medicine* 2021;100, :e25149.
- 23 Sweid A, Starke RM, Herial N, *et al.* Predictors of complications, functional outcome, and morbidity in a large cohort treated with flow diversion. *Neurosurgery* 2020;87:730–43.
- 24 Szikora I, Turányi E, Marosfoi M. Evolution of flow-diverter endothelialization and thrombus organization in giant fusiform aneurysms after flow diversion: a histopathologic study. *AJNR Am J Neuroradiol* 2015;36:1716–20.
- 25 Primiani CT, Ren Z, Kan P, *et al.* A2, M2, P2 aneurysms and beyond: results of treatment with pipeline embolization device in 65 patients. *J Neurointerv Surg* 2019;11:903–7.
- 26 Dandapat S, Mendez-Ruiz A, Martínez-Galdámez M, *et al.* Review of current intracranial aneurysm flow diversion technology and clinical use. *J Neurointerv Surg* 2021;13:54–62.
- 27 Han J, Chen J, Tong X, *et al.* Morphological characteristics associated with ruptured intracranial vertebral artery dissecting aneurysms. *J Neurointerv Surg* 2023;15:321–4.
- 28 Ge H, Chen X, Liu K, *et al.* Endovascular treatment of large or giant basilar artery aneurysms using the pipeline embolization device: complications and outcomes. *Front Neurol* 2022;13:843839. .
- 29 West NEJ, Ruygrok PN, Disco CMC, *et al.* Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. *Circulation* 2004;109:867–73.
- 30 Lauzier DC, Cler SJ, Osbun JW, *et al.* Management of in-stent stenosis with dual antiplatelet therapy following pipeline embolization of intracranial aneurysms. *World Neurosurg* 2022;167:e303–9.

Definition of anterior-circulation aneurysm and posterior-circulation aneurysm

Aneurysms located at the internal carotid artery, anterior communicating artery, posterior communicating artery, anterior cerebral artery, and middle cerebral artery were defined as anterior-circulation aneurysms. Aneurysms located at the vertebral artery, basilar artery, posterior inferior cerebellar artery, and posterior cerebral artery were defined as posterior-circulation aneurysms.

Definition of aneurysm and parental artery morphology parameters

The morphology parameters assessed in this study were defined as follows:

Aspect ratio: aneurysm height \div aneurysm width;

size ratio: maximum diameter of aneurysm \div parental artery diameter;

height/width ratio: perpendicular height of aneurysm \div aneurysm width;

bottle/neck factor: aneurysm neck length \div aneurysm width;

neck ratio: aneurysm neck length \div parental artery diameter;

mean artery diameter: (distal artery diameter + proximal artery diameter) \div 2;

artery difference: proximal artery diameter – distal artery diameter;

proximal-distal ratio: proximal artery diameter \div distal artery diameter.

All parameters were measured and calculated based on original digital subtraction angiography photographs.

Study Size Calculation

No sample size calculation was performed and the sample size was established by the time window of the study.

Platelet function test statement

The experimental diagnostic center at our hospital does not support PRU (P2Y12 reaction units) testing at present. Instead, all patients in our study underwent platelet function monitoring 1 day before PED placement. Platelet function was assessed by standard light transmittance aggregometry (LTA) to measure platelet aggregation. Light transmittance aggregometry was conducted using platelet-rich plasma using the turbidimetric method in a 4-channel aggregometer (AG800; Techlink Biomedical, Inc., Beijing, China). Maximal platelet aggregation (MPA) was defined as the percentage change in light transmittance. Subsequently, non-responders were defined as having an MPA response to ADP (adenosine diphosphate) of >50%. For those patients, clopidogrel was switched to one dose of ticagrelor (180 mg) before the procedure, followed by twice daily doses of ticagrelor (45 mg) after the procedure combined with aspirin (100 mg) for 6 months.

Statement for generation of PED used in this study

Pipeline Embolization Device and Pipeline Flex Embolization Device were used in our study without include PED Shield (Pipeline embolization device with Shield technology).

PED implantation procedure

The PED was delivered and deployed through a Marksman™ microcatheter (Medtronic, Irvine, CA) or an Excelsior™ XT-27™ microcatheter (Stryker, Kalamazoo, MI). PED-assisted coiling was considered if there was (a) a risk of shortening and displacement of the PED after release or (b) rapid blood flow (jet) at the aneurysmal neck on angiography, which was expected to pose a high risk of recurrence and postoperative bleeding with FD implantation alone. The brands of coil included Axium™ (Medtronic, Dublin, Ireland), Microplex™ (Microvention, Aliso Viejo, CA), Target™ (Stryker, Kalamazoo), and Orbit™ (Johnson & Johnson, New Brunswick, NJ). When full vessel wall apposition was not

achieved, stent massage or balloon angioplasty was performed.

Antiplatelet therapy after PED implantation

The duration of dual antiplatelet therapy (DAPT) after PED implantation was 6 months for aspirin (100 mg/day) combined with clopidogrel (75 mg/day), and aspirin (100 mg/day) was continued for at least 1 year. For patients with inadequate platelet inhibition with clopidogrel (platelet function test showed maximal platelet aggregation of >50%), clopidogrel was switched to one dose of ticagrelor (180 mg) before the procedure, followed by twice daily doses of ticagrelor (45 mg) for 6 months after the procedure. In fact, some patients with poor adherence spontaneously withdrew the antiplatelet drugs. We have added these data to our revised manuscript. The duration and type of antiplatelet therapy have been included in the manuscript and analyzed as variables

Analysis for drug withdraw between Non-ISS and ISS group

	No-ISS	ISS	Total	P value
Drug withdraw	82 (21.03%)	21 (30.43%)	103 (22.44%)	0.116

Univariate logistic regression	OR	95% CI	P value
Drug withdraw	1.641	0.932—2.903	0.116

Analysis for clopidogrel switched to ticagrelor between Non-ISS and ISS group

	No-ISS	ISS	Total	P value
Clopidogrel switched to ticagrelor	58 (14.9%)	14 (20.3%)	72 (15.7%)	0.254

Univariate logistic regression	OR	95% CI	P value
Clopidogrel switched to ticagrelor	1.457	0.762—2.789	0.256

69 **Subgroup analysis**

70

71 **Subgroup analysis for the average duration of follow-up between resolution**
72 **group vs non-resolution group in ISS patients**

73 There was a significant difference between the resolution group and the non-resolution group
74 (25 [14–36] months vs. 14 [9–20] months; P = 0.005) in terms of the average duration of
75 follow-up in patients with ISS. According to the ST-T curve, patients who developed ISS
76 showed a clear trend toward resolution 24 months after PED implantation, which is in line
77 with the statistical data.

78

79 **Subgroup analysis for the difference in resolution and progression to artery**
80 **occlusion between ISS patients who were on DAPT and non-DAPT**

81 Patients who had ISR had a higher rate of resolution if they extended their dose or resumed
82 DAPT (4 [7.8%] vs. 5 [27.8%]; P = 0.045). For patients with ISS who developed parental
83 artery occlusion, there was no significant difference between the aspirin group and the DAPT
84 group (12 [22.6%] vs. 6 [26.1%]; P = 0.240).

	Non-DAPT	DAPT	Total	P value
ISS to resolution	4 (7.8%)	5 (27.8%)	9 (13.0%)	0.045
ISS to occlusion	12 (22.6%)	6 (37.5%)	18 (26.1%)	0.240

85

86 **Subgroup analysis for the difference between responders and non-responders**
87 **(according to the platelet function test) respect to ISR**

88 There was no difference between responders and non-responders with respect to ISR in the
89 subgroup analysis (55 [14.2%] vs. 14 [19.4%]; P = 0.254)

	Responders	Non-responders	Total	P-value
In stent-stenosis	55 (14.2%)	14 (19.4%)	69 (15.0%)	0.254

90

91 **Evaluation of the ISS patients for proximal or distal "fishmouthing" and diffuse**
92 **or focal mechanical distortion of the actual Pipeline Embolization Device**

93

Types of in-stent stenosis	Numbers of patients (%)	Numbers of patients developed to parental artery occlusion (%)
Tissue growth in normal appearing PED	40 (57.97%)	0 (0.00%)
Proximal distortion (fish-mouthing) of the PED	9 (13.04%)	8 (44.4%)
Distal distortion (fish-mouthing) of the PED [#]	14 (20.29%)	8 (44.4%)
Distortion of the mid-portion of the PED	3 (4.35%)	1 (5.56%)
Tissue growth with distal distortion of the PED	2 (2.90%)	1 (5.56%)
Tissue growth with proximal distortion of the PED	1 (1.45%)	0 (0.00%)
Total	69 (100%)	18 (100%)

94 [#]The type of ISS was evaluated as distal distortion (fish-mouthing) of the PED in two patients that
 95 died.

96

97 After further back-to-back blinded review of follow up angiography of 69 patients with ISS,
 98 we found that 40 (57.97%) patients presented with tissue growth in normal appearing PED,
 99 nine (13.04%) patients had proximal distortion (fish-mouthing) of the PED, 14 (20.29%)
 100 patients had distal distortion (fish-mouthing) of the PED, and three (4.35%) patients had
 101 distortion of the mid-portion of the PED. Furthermore, two (2.90%) patients had normal
 102 tissue growth with distal distortion of the ISS, and one (1.45%) patient had tissue growth with
 103 proximal distortion of the PED. For the 18 patients who developed parental artery occlusion,
 104 dynamic assessment of postoperative follow-up angiography showed eight (44.44%) patients
 105 with proximal distortion (fish-mouthing) of the PED, eight (44.44%) patients with distal
 106 distortion (fish-mouthing) of the PED, and one (5.56%) patient with distortion of the
 107 mid-portion of the PED. One (5.56%) patient presented with normal tissue growth with distal
 108 distortion of the PED.

109

110 Interestingly, we found that nearly 2/3 of patients presenting with late stent distortion had
 111 their procedure between 2015–2018, with many Chinese physicians having only 1–3 years of

112 experience in using PEDs. At that time, some of the physicians used the biaxial system (e.g., a
113 6F guiding catheter combined with a Marksman micro catheter) to deliver and deploy the
114 PEDs. Although the biaxial system is the classic approach in cerebrovascular interventions, it
115 has poor support in curved vessels, which can lead to poor PED apposition. Furthermore,
116 even if the PED achieves an adequate apposition, the operator has to perform more pushing
117 and pulling maneuvers, which can increase the risk of irreversible damage to the PED
118 structure (e.g., twisting in the middle of the stent). Finally, the distal or proximal part of the
119 PED can be occasionally or inevitably placed into the curved vessel area of patients with a
120 tortuous blood vessel. All these factors can lead to late distortion of the PED.

121

122 When selecting the PED size, the operator will often measure the proximal and distal parental
123 artery diameters. However, to achieve adequate proximal wall apposition, the operator often
124 prefers to accommodate the proximal parental artery diameter. This inevitably results in a
125 ‘mismatch’ between the PED size and the distal vessel diameter, while the pressure from stent
126 expansion can result in intima damage at the distal part of the stent. We believe that these
127 factors may account for the greater number of patients with distal distortions than proximal
128 distortions.

129

130 To prevent the late mechanical distortion of the PED, we recommend that the operator use a
131 triaxial system to deliver and release the PED (e.g., the Neuron MAX 088 catheter combined
132 with the Navien intracranial support catheter and the Phenom-27 microcatheter). If poor wall
133 apposition is identified intraoperatively, the microguide wire massage stent should be used
134 carefully (careless handling can cause damage to the proximal part of the stent and may lead
135 to proximal distortion), and balloon-angioplasty or even further stent deployment (e.g.,
136 Neuroform EZ) should be used to achieve adequate apposition. Note that this additional
137 manipulation is also associated with increased risk of ISS.

138

Supplementary Table 1-1. Aneurysm characteristics of patients after PED treatment

Characteristics	Non-ISS (n=390)	ISS (n=69)	Total (n=459)	P value
Aneurysm location				0.008
ACA	2 (0.5%)	0 (0%)	2 (0.4%)	
AComA	1 (0.3%)	0 (0%)	1 (0.2%)	
BA	10 (2.6%)	2 (2.9%)	12 (2.6%)	
ICA	298 (76.4%)	40 (58%)	338 (73.6%)	
MCA	8 (2.1%)	2 (2.9%)	10 (2.2%)	
PCA	2 (0.5%)	1 (1.4%)	3 (0.7%)	
PComA	2 (0.5%)	0 (0%)	2 (0.4%)	
PICA	0 (0%)	2 (2.9%)	2 (0.4%)	
VA	67 (17.2%)	22 (31.9%)	89 (19.4%)	
Aneurysm position				0.390
middle	11 (2.9%)	2 (2.9%)	13 (2.8%)	
left	207 (53.1%)	30 (43.5%)	237 (51.6%)	
right	172 (44.1%)	37 (53.6%)	209 (45.5%)	
Aneurysm type				0.001
saccular	316 (81.03%)	44 (63.77%)	360 (78.43%)	
fusiform	74 (18.97%)	25 (36.23%)	99 (21.57%)	
Aneurysm in bifurcation	16 (4.1%)	5 (7.2%)	21 (4.6%)	0.401
Aneurysm with lobulation	43 (11.0%)	8 (11.6%)	51 (11.1%)	0.890
Aneurysm with daughter sac	28 (7.2%)	5 (7.2%)	33 (7.2%)	1.000
Multiple aneurysms	116 (29.7%)	18 (26.1%)	134 (29.2%)	0.538
Symptomatic aneurysms	172 (44.1%)	35 (50.7%)	207 (45.1%)	0.308
Recurrent Aneurysms	7 (1.8%)	2 (2.9%)	9 (2.0%)	0.890

139 ACA: anterior cerebral artery; AComA: anterior communicating artery; MCA: middle cerebral artery; ICA:

140 internal carotid artery; VA: vertebral artery; BA: basilar artery; PICA: posterior inferior cerebellar

141 artery; PComA: posterior communicating artery; PCA: posterior cerebral artery


Supplementary Table 1-2. Aneurysm characteristics of patients after PED treatment

Characteristics	Non-ISS (n=390)	ISS (n=69)	Total (n=459)	P value
Unsatisfiable Device Deployment	11 (2.8%)	5 (7.2%)	16 (3.5%)	0.136
Balloon angioplasty	68 (17.4%)	21 (30.4%)	89 (19.4%)	0.012
PED associated with coiling	146 (37.4%)	29 (42.0%)	175 (38.1%)	0.469
Used PED>1	46 (11.8%)	9 (13.0%)	55 (12.0%)	0.769
Aneurysm Neck	6.69 (4.45—11.1 0)	10.10 (6.52—15.7 5)	7.04 (4.50—11.6 0)	P<0.001
Maximum Diameter	10.40 (6.29—16.7 0)	13.30 (9.07—22.2 0)	10.90 (6.40—17.1 0)	0.003
Aneurysm Height	7.37 (4.76—11.8 0)	7.87 (6.57—14.4 5)	7.43 (4.95—12.1 0)	0.025
Aneurysm Width	8.48 (4.81—14.6 3)	12.9 (6.80—20.9 5)	9.02 (5.07—15.3 0)	P<0.001
Aneurysm Perpendicular Height	6.96 (4.50—11.2 3)	7.87 (5.83—14.2 5)	7.18 (4.68—11.6 0)	0.017
Parental Artery Diameter	3.64 (3.16—4.17)	3.82 (3.30—4.36)	3.66 (3.17—4.19)	0.304
Proximal Artery Diameter	3.91 (3.45—4.49)	4.00 (3.15—4.79)	3.92 (3.42—4.53)	0.890
Distal Artery Diameter	3.43	3.49	3.44	0.327

	(3.04—3.86)	(2.82—4.22)	(2.98—3.88)	
Mean Artery Diameter	3.68	3.80	3.68	0.702
	(3.21—4.08)	(3.19—4.36)	(3.21—4.09)	
Difference between Proximal and Distal Artery	0.45	0.49	0.46	0.882
	(0.09—1.01)	(0.06—1.08)	(0.09—1.01)	
Proximal/Distal Ratio	1.13	1.12	1.13	0.900
	(1.03—1.30)	(1.02—1.34)	(1.03—1.31)	
Aspect Ratio	1.07	0.94	1.04	0.141
	(0.74—1.59)	(0.66—1.50)	(0.73—1.59)	
Height/Width Ratio	0.89	0.81	0.87	0.012
	(0.74—1.02)	(0.64—0.95)	(0.72—1.01)	
Bottle Neck Factor	0.94	1.00	0.95	0.865
	(0.69—1.00)	(0.68—1.00)	(0.69—1.00)	
Size Ratio	2.87	3.56	3.00	0.007
	(1.64—4.73)	(2.18—6.32)	(1.73—4.81)	
Neck Ratio	1.91	2.93	1.99	P<0.001
	(1.15—3.02)	(1.56—4.40)	(1.19—3.40)	

PED: Pipeline Embolization Device

Supplementary Figure 1 Flow Chart



ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Siming Gui

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Xiheng Chen

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Dachao Wei

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Dingwei Deng

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Wei You

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Xiangyu Meng

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Jian Lv

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Junqiang Feng

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Yudi Tang

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Shu Yang

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Ting Chen

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> </div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> </div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> </div>	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/30/2022

Your Name:Liu Peng

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Huijian Ge

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Hengwei Jin

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div></div> <div></div> <div></div>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Xinke Liu

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Yuhua Jiang

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known):jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Wei Feng

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> <div></div> </div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> <div></div> </div>	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <div> <div></div> <div></div> <div></div> </div>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date:12/10/2022

Your Name:Youxiang Li

Manuscript Title:Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline Embolization Device treatment of intracranial aneurysm

Manuscript Number (if known): jnis-2022-019680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div><input type="checkbox"/> None</div> <table><tr><td>the National Key Research and Development Program of China (grant No. 2017YFB1304400).</td><td>Payment for the article processing charges</td></tr><tr><td></td><td></td></tr><tr><td></td><td>Click the tab key to add additional rows.</td></tr></table>	the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges				Click the tab key to add additional rows.	
the National Key Research and Development Program of China (grant No. 2017YFB1304400).	Payment for the article processing charges							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							
3	<div>Royalties or licenses</div> <div><input checked="" type="checkbox"/> None</div> <table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.